• Susan E Conway, Scott E Schaeffer, and Donald L Harrison.
• University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA.
• Ann Pharmacother. 2014 Mar 1;48(3):354-60.

BackgroundDabigatran is a novel oral anticoagulant for which a well-defined range of toxicity and proven antidote has not been established.ObjectiveThe primary objective of this study was to characterize dabigatran exposures reported to poison centers by dose ingested, clinical effects, treatments used, and managment sites to gain a better understanding of patient outcomes.MethodsA retrospective database review was conducted for dabigatran exposures reported to the National Poison Data System for the American Association of Poison Control Centers (AAPCC) over the period October 2010 to December 2012.ResultsThere were 802 human dabigatran exposures involving adults predominantly (91% of cases). Exposure chronicity was acute in 43%, acute-on-chronic in 46%, and chronic in 11%, with the most common reason for an exposure call being an unintentional therapeutic error (70.6%). The most common management sites were on-site in 72% of cases and within a health care facility for 26%. Bleeding events and coagulopathies were the most commonly observed clinical effects. Treatments administered included activated charcoal, blood and coagulation products, hemodialysis, and supportive measures. Confirmed outcomes included death in 13 patients (1.6%), major effects in 23 (2.9%), and moderate effects in 50 (6.2%). More severe outcomes were significantly associated with adverse drug reactions, patients ≥65 years of age, those treated with blood and coagulation products and/or dialysis, and renal dysfunction (P < .05). Children experienced few moderate effects and no major effects or deaths.ConclusionsSevere outcomes from dabigatran exposures were not common, occurring in approximately 5% of cases.

29 keywords...

hide…